86734
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
≥97.0% (CHN)
Synonym(s):
DOTA
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H28N4O8 · xH2O
CAS Number:
Molecular Weight:
404.42 (anhydrous basis)
UNSPSC Code:
12352005
NACRES:
NA.22
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1186987
Assay:
≥97.0% (CHN)
Form:
powder
Quality Level
assay
≥97.0% (CHN)
form
powder
functional group
carboxylic acid
SMILES string
OC(=O)CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(O)=O
InChI
1S/C16H28N4O8/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)
InChI key
WDLRUFUQRNWCPK-UHFFFAOYSA-N
Application
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a macrocyclic complexing agent.
- It has been used for radiolabeling of carbon nanotube bioconjugates by chelating 64Cu radioisotope.
- DOTA can be activated with N-hydroxysulfosuccinimidyl for conjugation with monoclonal antibodies in clinical radioimmunotherapy.
- It can form complexes with gadolinium for application as MRI contrast agents.
- Metal complexes of DOTA-peptide conjugates can be used as therapeutic radiopharmaceuticals.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents.
Laus S, et al.
Chemistry?A European Journal , 9(15), 3555-3566 (2003)
Preparation of carbon nanotube bioconjugates for biomedical applications.
Liu Z, et al.
Nature Protocols, 4(9), 1372-1372 (2009)
Nicholas P van der Meulen et al.
Molecules (Basel, Switzerland), 25(20) (2020-10-18)
44Sc has favorable properties for cancer diagnosis using Positron Emission Tomography (PET) making it a promising candidate for application in nuclear medicine. The implementation of its production with existing compact medical cyclotrons would mean the next essential milestone in the